Shionogi study links edaravone to improved progression-free survival in ALS patients

• Shionogi will present three ALS research posters at the 2026 Annual NEALS Meeting, October 27-30 in Clearwater, Florida.
• Real-world analyses associate Radicava ORS treatment with longer survival without disease progression and slower functional decline in patients with ALS.
• At-home respiratory monitoring research identifies a lung-function benchmark that could help distinguish patients at risk of faster disease progression.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Shionogi & Co. Ltd. published the original content used to generate this news brief via Business Wire (Ref. ID: 202610260800BIZWIRE_USPR_____20261026_BW530004) on October 26, 2026, and is solely responsible for the information contained therein.